Cardiff Oncology, Inc. (CRDF) 2015年年度报告「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 Form 10-K(Mark One)x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31,2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF

2、1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-54556TROVAGENE,INC.(Exact name of registrant as specified in its charter)Delaware 27-2004382(State or other jurisdiction of(I.R.S.Employerincorporation or organization)Identification No.)11055 Flintkote Avenue,Suite B,San Diego,Califo

3、rnia 92121(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:(858)952-7570 Securities registered pursuant to Section 12(b)of the Act:Title of each class Name of each exchange on which registered Units,each consisting of two shares of Common Stock andon

4、e Warrant to purchase one share of Common Stock The NASDAQ Capital Market Common Stock,$0.0001 par value The NASDAQ Capital Market Warrants to purchase Common Stock The NASDAQ Capital Market Securities registered pursuant to Section 12(g)of the Act:None.Indicate by check mark if the registrant is a

5、well-known seasoned issuer,as defined in Rule 405 of the Securities Act Yes o No x Indicate by check if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes o No x Indicate by check mark whether the registrant(1)has filed all reports required to be fil

6、ed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filingrequirements for the past 90 days.Yes x No o Indicate by check mark whether the registr